Vivek Subbiah, Chief of Early-Phase Drug Development at the Sarah Cannon Research Institute, shared Caris Life Sciences post on LinkedIn, adding:
“Tissue-agnostic cancer therapies are revolutionizing oncology!
Mark your calendars! Join Theodore Nicolaides and me in the Caris Life Sciences webinar discussing breakthrough research published in Nature Communications on precision medicine’s promise and reality.
New real-world study: 21.5% of 300K tumors have tissue-agnostic indications. Despite 9 FDA approvals, implementation challenges persist.”
Title: Real-world evidence provides clinical insights into tissue-agnostic therapeutic approvals
Article: George W. Sledge Jr., Takayuki Yoshino, Joanne Xiu, Anthony Helmstetter, Jennifer R. Ribeiro, Sergey Klimov, Brady Gilg, JJ Gao, Jeff Elton, Matthew J. Oberley, Milan Radovich, Jim Abraham, David Spetzler
Read the Full Article on Nature Communications
Quoting Caris Life Sciences’s post:
“Don’t miss out!
Discover how real-world data is transforming tissue-agnostic cancer care.
Join Theodore Nicolaides, MD, Senior Medical Director and Vivek Subbiah, MD, Chief Early Phase Drug Development at Sarah Cannon Research Institute as they discuss the future of precision oncology featuring insights from Dr. Subbiah’s ‘Nature Communications’ commentary and Caris-led research on pan-tumor biomarkers.
Register now.”
Title: Tissue-agnostic cancer therapies: promise, reality, and the path forward
Author: Vivek Subbiah
Read the Full Article on Nature Communications
More posts featuring Caris Life Sciences.
